Global Anticancer Drugs Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

List of Tables

The global demand for Anticancer Drugs Market is presumed to reach the market size of nearly USD 390.27 BN by 2032 from USD 157.61 BN in 2023 with a CAGR of 10.6% under the study period 2024 - 2032.

Anticancer drugs, also known as chemotherapy or cancer-fighting drugs, are medications designed to target and destroy cancer cells in the body. They are a crucial component of cancer treatment, often used in combination with other therapeutic approaches like surgery, radiation therapy, or immunotherapy.

MARKET DYNAMICS

The Anticancer drugs market is experiencing significant growth driven by multiple factors. A primary catalyst is the escalating global incidence of cancer, necessitating effective and advanced treatment options. Technological advancements in drug development, particularly the emergence of targeted therapies and immunotherapies, have transformed cancer treatment, fostering a demand for innovative drugs that specifically target cancer cells. The aging global population contributes substantially to market expansion, given the higher prevalence of cancer in older individuals. Increased awareness and early cancer detection also play a pivotal role, enabling more effective treatment with anticancer drugs. Government initiatives and investments in cancer research further drive market growth, with a focus on improving accessibility to cancer treatment.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of anticancer drugs. The growth and trends of anticancer drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the anticancer drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Type

Cytotoxic Drugs (Alkylating Agerits, Antimetabolites, Others)
Targeted Drugs (Monodional Antibodies, Tyrosine Kinase Inhibitors, Others)
Hormonal Drugs

By Therapy Type

Chemotherapy
Targeted Therapy
Immunotherapy
Others

By Cancer Type

Lung Cancer
Breast Cancer
Leukemia
Colorectal Cancer
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Anticancer Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Anticancer Drugs market include Amgen Inc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., Bayer AG, Merck & Co Inc, Celgene Corporation. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR112113377

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . ANTICANCER DRUGS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Type
- 3.7.2 Market Attractiveness Analysis By Therapy Type
- 3.7.3 Market Attractiveness Analysis By Cancer Type
- 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL ANTICANCER DRUGS MARKET ANALYSIS BY DRUG TYPE

5.1 Overview by Drug Type
5.2 Historical and Forecast Data
5.3 Analysis by Drug Type
5.4 Cytotoxic Drugs (Alkylating Agerits, Antimetabolites, Others) Historic and Forecast Sales by Regions
5.5 Targeted Drugs (Monodional Antibodies, Tyrosine Kinase Inhibitors, Others) Historic and Forecast Sales by Regions
5.6 Hormonal Drugs Historic and Forecast Sales by Regions

6 . GLOBAL ANTICANCER DRUGS MARKET ANALYSIS BY THERAPY TYPE

6.1 Overview by Therapy Type
6.2 Historical and Forecast Data
6.3 Analysis by Therapy Type
6.4 Chemotherapy Historic and Forecast Sales by Regions
6.5 Targeted Therapy Historic and Forecast Sales by Regions
6.6 Immunotherapy Historic and Forecast Sales by Regions
6.7 Others Historic and Forecast Sales by Regions

7 . GLOBAL ANTICANCER DRUGS MARKET ANALYSIS BY CANCER TYPE

7.1 Overview by Cancer Type
7.2 Historical and Forecast Data
7.3 Analysis by Cancer Type
7.4 Lung Cancer Historic and Forecast Sales by Regions
7.5 Breast Cancer Historic and Forecast Sales by Regions
7.6 Leukemia Historic and Forecast Sales by Regions
7.7 Colorectal Cancer Historic and Forecast Sales by Regions
7.8 Others Historic and Forecast Sales by Regions

8 . GLOBAL ANTICANCER DRUGS MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1. Overview, Historic and Forecast Data Sales Analysis
- 8.3.2. North America By Segment Sales Analysis
- 8.3.3. North America By Country Sales Analysis
- 8.3.4. United State Sales Analysis
- 8.3.5. Canada Sales Analysis
- 8.3.6. Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1. Overview, Historic and Forecast Data Sales Analysis
- 8.4.2. Europe by Segment Sales Analysis
- 8.4.3. Europe by Country Sales Analysis
- 8.4.4. United Kingdom Sales Analysis
- 8.4.5. France Sales Analysis
- 8.4.6. Germany Sales Analysis
- 8.4.7. Italy Sales Analysis
- 8.4.8. Russia Sales Analysis
- 8.4.9. Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1. Overview, Historic and Forecast Data Sales Analysis
- 8.5.2. Asia Pacific by Segment Sales Analysis
- 8.5.3. Asia Pacific by Country Sales Analysis
- 8.5.4. China Sales Analysis
- 8.5.5. India Sales Analysis
- 8.5.6. Japan Sales Analysis
- 8.5.7. South Korea Sales Analysis
- 8.5.8. Australia Sales Analysis
- 8.5.9. South East Asia Sales Analysis
- 8.5.10. Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1. Overview, Historic and Forecast Data Sales Analysis
- 8.6.2. Latin America by Segment Sales Analysis
- 8.6.3. Latin America by Country Sales Analysis
- 8.6.4. Brazil Sales Analysis
- 8.6.5. Argentina Sales Analysis
- 8.6.6. Peru Sales Analysis
- 8.6.7. Chile Sales Analysis
- 8.6.8. Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1. Overview, Historic and Forecast Data Sales Analysis
- 8.7.2. Middle East & Africa by Segment Sales Analysis
- 8.7.3. Middle East & Africa by Country Sales Analysis
- 8.7.4. Saudi Arabia Sales Analysis
- 8.7.5. UAE Sales Analysis
- 8.7.6. Israel Sales Analysis
- 8.7.7. South Africa Sales Analysis
- 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE ANTICANCER DRUGS COMPANIES

9.1. Anticancer Drugs Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10 . COMPANY PROFILES OF ANTICANCER DRUGS INDUSTRY

10.1. Company Share Analysis
10.2. Market Concentration Rate
10.3. Amgen Inc
- 10.3.1. Company Overview
- 10.3.2. Company Revenue
- 10.3.3. Products
- 10.3.4. Recent Developments
10.4. Takeda Pharmaceutical Company Limited
- 10.4.1. Company Overview
- 10.4.2. Company Revenue
- 10.4.3. Products
- 10.4.4. Recent Developments
10.5. Eli Lilly and Company
- 10.5.1. Company Overview
- 10.5.2. Company Revenue
- 10.5.3. Products
- 10.5.4. Recent Developments
10.6. F. Hoffmann-La Roche Ltd.
- 10.6.1. Company Overview
- 10.6.2. Company Revenue
- 10.6.3. Products
- 10.6.4. Recent Developments
10.7. Novartis AG
- 10.7.1. Company Overview
- 10.7.2. Company Revenue
- 10.7.3. Products
- 10.7.4. Recent Developments
10.8. Pfizer Inc.
- 10.8.1. Company Overview
- 10.8.2. Company Revenue
- 10.8.3. Products
- 10.8.4. Recent Developments
10.9. Bayer AG
- 10.9.1. Company Overview
- 10.9.2. Company Revenue
- 10.9.3. Products
- 10.9.4. Recent Developments
10.10. Merck & Co Inc
- 10.10.1. Company Overview
- 10.10.2. Company Revenue
- 10.10.3. Products
- 10.10.4. Recent Developments
10.11. Celgene Corporation
- 10.11.1. Company Overview
- 10.11.2. Company Revenue
- 10.11.3. Products
- 10.11.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies